Menu

Natasha Leskovsek

Of Counsel

I’ve taken my clinical and consulting experience for pharma and biotech companies on regulatory issues and brought them to Cooley’s clients.

+1 202 728 7131
nleskovsek@cooley.com

Natasha Leskovsek advises pharmaceutical, biotechnology, medical device and food/dietary supplement industry clients on US Food and Drug Administration regulatory and clinical development matters. She also conducts regulatory diligence on behalf of entities investing in FDA-regulated companies.

Download full bio 

Experience

  • Lyell Immunopharma – $425 Million IPO 

  • The Honest Company – $475 Million IPO 

  • Five Prime Therapeutics Agrees to Sell to Amgen for $1.9 Billion 

  • Horizon Therapeutics to Acquire Viela Bio 

  • Celularity to Go Public Through SPAC Merger 

  • View all

Practices & Industries
Passions

    Providing practical compliance solutions at the intersection of science and regulation

Education

  • Georgetown University Law Center
    JD, 1996

  • University of Maryland, College Park
    MBA, 1991

  • University of Maryland, College Park
    MPM, 1991

  • University of Maryland, Baltimore
    BSN, 1989

Admissions & Credentials

District of Columbia

Maryland

Media & Insight
Memberships

  • American Health Lawyers Association

  • Food and Drug Law Institute

contact

+1 202 728 7131 office
+1 202 842 7899 fax
nleskovsek@cooley.com

1299 Pennsylvania Avenue, NW
Suite 700
Washington, DC 20004-2400